When to Notify MHRA of Changes for UK Medical Device Registration?

When to Notify MHRA of Changes for UK Medical Device Registration?

After a medical device is registered with the UK MHRA, any change that may affect the safety, performance, labeling, intended purpose, production conditions, quality management system, or UK Responsible Person (UKRP) information must be evaluated for notification. The core criterion is whether the change could have a material impact on the product's risk status or conformity. Companies must classify changes per MHRA's Change Guidance: significant changes (e.g., design, materials, sterilization, intended use, software algorithm, shelf life, performance specifications) require prior application and may necessitate a new certificate; moderate changes (e.g., supplier replacement, manufacturing site relocation, non-substantial label updates) require notification but not necessarily suspension of sales; minor changes (e.g., administrative information updates) can be reported in the annual update. Submission must include change description, risk assessment, affected technical documentation updates, verification summaries, and declaration of conformity. Common risks include misclassification leading to non-notification, use of outdated standards, omission of UKRP changes, and failure to consider linkages with CE or MDR changes. Companies should establish an internal change classification process, synchronize with UKRP, and retain all evidence for audits.

Key Summary

• Core principle: Notify MHRA of any change that materially impacts risk status or conformity.
• Classification: Significant (pre-approval), Moderate (notification), Minor (annual update).
• Typical significant changes: Design, materials, sterilization, intended use, software algorithm, shelf life, performance.
• Moderate changes: Supplier change, site relocation, non-substantial label updates.
• Minor changes: Administrative updates (e.g., company address).

Applicable Scenarios and Core Issues

Not all changes require immediate notification. Key questions: Which changes must be proactively reported? Which can wait for annual update? Which could invalidate the registration or lead to market withdrawal? Scenarios include design changes, material changes, process optimization, supplier replacement, software updates, sterilization method changes, intended use adjustments, packaging changes, labeling revisions, production site relocation, quality system standard upgrades (e.g., ISO 13485:2016 to 2021), and UKRP changes.

Decision Logic for Change Notification

Follow these steps: (1) Determine if product still qualifies as a medical device; (2) Assess impact on risk classification; (3) Evaluate effect on Essential Safety and Performance Requirements (ESPs); (4) Check if change affects core technical documentation (design, materials, sterilization, etc.); (5) Consider existing certificates (CE, UKCA); (6) Evaluate QMS changes; (7) Confirm UKRP information; (8) Assess multi-market applicability; (9) Keep records of decisions; (10) If uncertain, submit a Change Notification Inquiry to MHRA.

Documentation and Evidence

Prepare: change description, risk assessment per ISO 14971, verification reports (e.g., electrical safety, biocompatibility, sterilization validation, software validation), updated labeling drafts, QMS change records, updated Declaration of Conformity, clinical evidence if applicable, UKRP confirmation letter. All documents in English or certified translation. Retain original data for at least five years.

Common Mistakes

• Misclassifying significant changes as moderate/minor (e.g., sterilization supplier change without revalidation).
• Ignoring software changes (algorithm, function, UI).
• Applying EU change guidance instead of UK-specific MHRA rules.
• Failing to update UKRP changes on the certificate.
• Not updating labels after changes (e.g., date format, packaging size).
• Not reporting QMS standard transition (e.g., ISO 13485 version change).
• Adding a new production site without notification.
• Overlooking increased adverse events post-change requiring reporting.

Company Preparedness Checklist

• Establish a change management SOP with clear roles (R&D, Quality, Regulatory, Operations, UKRP).
• Create a change classification table aligned with MHRA guidance.
• Ensure risk assessment and documentation for every change.
• Maintain agreement with UKRP for timely notification.
• Prepare template documents (change request, risk assessment, verification summary).
• Train regulatory team on current MHRA guidance.
• Coordinate multi-market changes via a global change tracker.
• Summarize minor and moderate changes in annual update.
• Keep baseline technical documentation for comparison.
• Audit change management effectiveness regularly.

AIMEILI Regulatory Interpretation and Business Impact

Companies most frequently underestimate the severity of software, supplier, and labeling changes. Many assume internal validation suffices, ignoring MHRA’s pre-notification requirements. We recommend establishing an internal change classification system prior to project initiation, referencing MHRA’s Change Guidance, and aligning with UKRP regularly. Core technical files (design, risk management, performance) can be reused across markets, but assessment of UK-specific regulatory differences (e.g., UK MDR 2002) must be localized. Special attention: certificate control lies with the registration holder; UKRP replacement or contact changes must be updated immediately to avoid certificate invalidation. For multi-country products, complete core technical changes first, then adapt per country; use a global change dashboard to track requirements, submission status, and approvals.

Frequently Asked Questions

Q: Can minor changes be omitted from notification?
A: Minor changes (e.g., company address change, new factory under same QMS) generally need not be notified immediately but must be included in the annual update. However, internal records must be kept and labels updated. MHRA may consider non-recording as non-compliance during audits.

Q: How long does change approval take?
A: Significant changes typically require 60–90 days; moderate changes may be processed within 30 days; minor changes are automatically accepted in the annual update. Timelines depend on complexity and MHRA workload. Submit significant changes at least 4 months in advance.

Q: Can changes affecting both CE and UKCA be submitted jointly?
A: No. CE and UKCA are separate systems; submissions must be made separately to EU notified bodies and MHRA. Core technical files can be shared, but UK-specific requirements must be addressed. Joint submission leads to confusion and increased deficiency risk.

Note: Based on MHRA guidance as of 2025; subject to updates.